Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?
Open Access
- 9 June 2021
- Vol. 13 (12), 2896
- https://doi.org/10.3390/cancers13122896
Abstract
Severe acute respiratory virus-2 (SARS-CoV-2) has spread globally leading to a devastating loss of life. Large registry studies have begun to shed light on the epidemiological and clinical vulnerabilities of cancer patients who succumb to or endure poor outcomes of SARS-CoV-2. Specific treatment for COVID-19 infections in cancer patients is lacking while the demand for treatment is increasing. Therefore, we explored the effect of Rintatolimod (Ampligen®) (AIM ImmunoTech, Ocala, FL, USA), a Toll-like receptor 3 (TLR3) agonist, to treat uninfected human pancreatic cancer cells (HPACs). The direct effect of Rintatolimod was measured by targeted gene expression profiling and by proteomics measurements. Our results show that Rintatolimod induces an antiviral effect in HPACs by inducing RNase-L-dependent and independent pathways of the innate immune system. Treatment with Rintatolimod activated the interferon signaling pathway, leading to the overexpression of several cytokines and chemokines in epithelial cells. Furthermore, Rintatolimod treatment increased the expression of angiogenesis-related genes without promoting fibrosis, which is the main cause of death in patients with COVID-19. We conclude that Rintatolimod could be considered an early additional treatment option for cancer patients who are infected with SARS-CoV-2 to prevent the complicated severity of the disease.Keywords
Funding Information
- ZonMw (440.20.010.)
This publication has 41 references indexed in Scilit:
- A Proteome Comparison Between Physiological Angiogenesis and Angiogenesis in GlioblastomaMolecular & Cellular Proteomics, 2012
- A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue SyndromePLOS ONE, 2012
- Toll like receptors in diseases of the lungInternational Immunopharmacology, 2011
- A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoVirology, 2009
- Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokinesMolecular Immunology, 2007
- ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway EpitheliaJournal of Virology, 2005
- Toll-Like Receptor 3 Is Induced by and Mediates Antiviral Activity against Rhinovirus Infection of Human Bronchial Epithelial CellsJournal of Virology, 2005
- Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patientsJournal of Biomedical Science, 2004
- Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:PolyC12U in the treatment of HIV infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytesNature, 1980